RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
TFA Therapeutics, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$9.18+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
TFA Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Revenue - products sales | $1.07M | $1.20M | $601.57K | – | – | 85.9% | -10.9% |
| Revenue - related parties | $175.41K | $52.94K | $126.86K | $53.30K | – | 14.1% | +231.3% |
| Sales of cordyceps | – | – | – | $448.79K | $879.32K | – | – |
| Revenue - training | – | – | $154.11K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of TFA Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.